Table 2.
Comparison of studies without pharmacist’s participation reported vs pharmacist intervention in patients with infantile hemangioma treated with propranolol
| Outcome | Pharmacist’s participation n = 63 | Without participation of the pharmacist reported [6] n = 456a | Without participation reported systematic review [7] n = 31b |
|---|---|---|---|
| Adherence to treatment | 90.5% | 79% | 86% |
| Adverse reactions reported | 12.3% | 33% | 31.2% |
| Successful response to treatment | 95% | 77.2% | 82% |
| Regrowth of hemangioma | 4.7% | 14% | 17% |
| Discontinuation of therapy | 2% | 10.5% | 4% |
| Duration of treatment (months) | 9.1 | 6.2 | 6.4 |
| Dosage administered | 0.5–2.5 mg/kg/day | 1–3 mg/kg/day | 1–4 mg/kg/day |
| Oral formulation | Extemporaneously compounded syrup | Hemangeol® oral solution | Oral solution, capsules, tablets |